| Autor: |
Karami, Hossein, Khalilzadeh Arjmandi, Hadiseh, Salehifar, Ebrahim, Darvishi‐Khezri, Hadi, Dabirian, Mojdeh, Kosaryan, Mehrnoush, Aliasgharian, Aily, Akbarzadeh, Rosetta, Naeimayi Aali, Raheleh, Nasirzadeh, Amirreza |
| Zdroj: |
International Journal of Clinical Practice; Aug2021, Vol. 75 Issue 8, p1-8, 8p |
| Abstrakt: |
Background and aim: This study examined whether administration of amlodipine could improve myocardial iron loading status in patients with transfusion dependent β‐thalassemia (TDT), through a placebo‐controlled, crossover study. Methods: Amlodipine (5 mg, daily) or placebo were prescribed to all patients (n = 19) for 6 months, and after a 2‐week washout period, patients were crossed over to the other group. The efficacy of amlodipine on iron loading was assessed by measuring myocardial T2*‐weighted magnetic resonance imaging (MRI T2*, millisecond [ms]) and serum ferritin (ng/mL). Results: Seventeen patients completed the study. The mean ± standard deviation [SD] of myocardial MRI T2* at baseline was 9.83 ± 2.67 ms Myocardial MRI T2* value rose to 11.44 ± 4.14 ms post amlodipine treatment in all patients. After placebo, myocardial MRI T2* value reached 10.29 ± 4.01 ms After controlling the baseline measures, Hedges's g for ferritin and myocardial MRI T2* outcomes were estimated 3.84 (95% confidence interval [CI] 2.68 to 4.97) and −1.80 (95% CI −2.58 to −0.10), respectively. Conclusion: Amlodipine might improve myocardial MRI T2* and serum ferritin level compared to placebo. However, larger clinical studies are needed to confirm the results. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
